Joint Infection Clinical Trial
Official title:
Bacterial Epidemiology and Empirical Antibiotherapy in Patients With Prosthetic Joint Infection
The purpose of this study is to establish a bacterial epidemiology in patients who present a
prosthetic joint infection and for which a surgery is necessary. At the time of the first
surgery, as the bacteria responsible for the infection are not known, a probabilistic
antibiotherapy is initiated at once after the surgical treatment. The antibiotherapy is then
adapted to the bacteria from samples collected during the surgery when they are identified
(the delay is 14-21 days).
The study will focus on bacteria identified on samples collected during the surgery; the
delay between the implantation of the prosthesis and the presentation of symptoms will be
considered : more than one year vs. less than one year.
Investigators assume that there is not the same type of bacteria involved in those two cases
of delays and that the probabilistic antibiotherapy may be not optimal when the symptoms are
presented more than one year after implantation of the prosthesis. A probabilistic
antibiotherapy not adapted lead to develop resistance for the bacteria and decrease the
chance to cure the patient (increasing of relapse).
The result of this study will allow medical doctors to have an optimal probabilistic
antibiotherapy, depending on the delay between implantation of the prosthesis and the
presentation of the symptoms.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05519007 -
Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone
|
N/A | |
| Active, not recruiting |
NCT04563325 -
Oral-only Antibiotics for Bone and Joint Infections in Children
|
Phase 4 | |
| Recruiting |
NCT05341908 -
Prevalence of Pathogens in Synovial Fluid Obtained From Emergency Department Patients
|
||
| Recruiting |
NCT03550911 -
Biological Collection From Samples From The Gut Microbiota In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine (CARBAMICROBIOTA)
|
||
| Completed |
NCT04440631 -
Gut Microbiome of Patients Undergoing Antibiotic Therapy for Orthopedic Device-related Infection
|
||
| Recruiting |
NCT05753215 -
Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection
|
Phase 2 | |
| Recruiting |
NCT05137314 -
Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)
|
Phase 1 | |
| Not yet recruiting |
NCT06293352 -
Real-component vs All-cement Articulating Spacers for Periprosthetic Knee Infection
|
N/A | |
| Recruiting |
NCT04304885 -
Effect of Sonication on Periprosthetic Joint Infection Treatment Strategy.
|
||
| Completed |
NCT03403608 -
Subcutaneous Suppressive Antibiotic Therapy for Bone and Joint Infections
|
N/A | |
| Recruiting |
NCT03704766 -
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
|
N/A | |
| Completed |
NCT00974493 -
Oral Versus Intravenous Antibiotics for Bone and Joint Infections (OVIVA B&J)
|
Phase 4 | |
| Recruiting |
NCT06191601 -
Interest in Probabilistic Antibiotic Therapy With Broad-spectrum Beta-lactams in Orthopedic Surgery
|
||
| Completed |
NCT05804058 -
Biofilm Composition as a Predictive Biomarker for Prosthetic Joint Infection
|
||
| Enrolling by invitation |
NCT04723940 -
Or v IV Antibiotics for Infection
|
Phase 3 | |
| Completed |
NCT03426761 -
Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections
|
Phase 4 | |
| Enrolling by invitation |
NCT03713528 -
Can Intraosseous Antibiotics Improve the Results of Irrigation & Debridement and Prosthetic Retention for PJI?
|
Phase 4 | |
| Completed |
NCT04948281 -
Joint Infection Following ACL Reconstruction
|
||
| Completed |
NCT06267287 -
Microbiological Structure of Pathogens of Periprosthetic Infection of Large Joints in the Post-Covid Period
|
||
| Terminated |
NCT03335592 -
Cost of Off-label Antibiotics in Osteoarticular Infections
|